CLAIM CARD
Mechanistically, the pharmacokinetic data from these studies support the development of fixed-dose combinations to improve patient adherence and simplify treatment regimens. The bioequivalence studies by Mei 2025, Tian 2025, Hu 2025, and Goh 2026 provide the foundational evidence for such formulations, ensuring comparable systemic exposure to the individual components (Mei 2025, Tian 2025, Hu 2025, Goh 2026). Preclinical and human data suggest that optimized dosing can achieve target receptor blockade while potentially minimizing off-target effects, a principle supported by the dose-dependent findings reported in the retrospective analysis by Kato 2025 on sacubitril/valsartan in heart failure (Kato 2025).
Evidence grade: exploratory
Contradiction status: none
Publication: edeb045d-18ed-49dc-95b6-57f76783ce2b
Provenance: Derivation Web chain
Citation Support
source_1Solomon 2026source_2Din 2026source_3Li 2025source_4Mei 2025source_5Chung 2024